AptarGroup, Inc. (ATR) Company Overview

What does AptarGroup do?

AptarGroup, Inc. is a New York Stock Exchange-listed manufacturer of drug-delivery, dispensing, dosing, sealing and active-material technologies. Its components sit between a customer’s formulation and the patient or consumer: nasal spray pumps, metered-dose inhaler valves, elastomeric components for injectable medicines, fragrance pumps, airless cosmetic systems, food and beverage closures, and protective packaging that manages moisture or oxygen. The company describes itself as a partner to leading pharmaceutical and consumer brands, and its official corporate overview emphasizes solutions that improve how products are delivered, dispensed and protected.

Why does a component supplier matter?

Aptar rarely owns the medicine or consumer brand; it solves the engineering problem around delivery. A pump must meter a consistent dose, protect the formulation, meet regulations and run reliably on a filling line. Pharma qualification can span development through approval, creating high documentation and performance requirements. Beauty and Closures compete more on aesthetics, convenience, recyclability and high-volume reliability.

The business is global and capital intensive. Europe generated 49% of FY2025 sales and 52% of Q1 2026 sales. The footprint supports local supply and customer launches, but adds currency, labor, tariff and operating-complexity exposure.

How does AptarGroup make money?

Aptar primarily earns product revenue by selling engineered components and systems to pharmaceutical, healthcare, beauty, personal-care, home-care, food and beverage customers. It also receives tooling revenue when customers fund molds or production preparation, and Pharma generates royalties and service revenue tied to proprietary technologies, drug-development support and intellectual property. The company’s broad product portfolio shows why the model is better understood as a collection of specialized platforms than as commodity packaging.

Which segment contributes the most?

Pharma is the economic engine. In FY2025 it supplied 69% of segment adjusted EBITDA before unallocated corporate costs, versus 18% from Beauty and 13% from Closures. Its 35.0% margin compared with 12.1% for Beauty and 16.0% for Closures. Consequently, a modest change in prescription, injectable or royalty revenue can outweigh a larger consumer-sales movement.

What does AptarGroup’s latest quarter show?

The latest available reporting package is the quarter ended March 31, 2026. Aptar’s first-quarter 2026 results showed reported sales growth but weaker profit margins. Reported sales rose 11% to $982.9 million, yet core sales were flat because currency added about eight percentage points and acquisitions added three. Net income declined 8% to $72.7 million, diluted EPS fell to $1.12 from $1.17, and adjusted EBITDA margin contracted to 19.2% from 20.7%.

Why did reported growth not translate into profit growth?

The Q1 2026 Form 10-Q identifies mix and operating costs as the key bridge. Cost of sales increased to 64.2% of revenue from 62.1%, operating margin declined to 10.9% from 12.8%, and interest expense rose to $16.9 million from $11.4 million. Pharma absorbed lower emergency-medicine sales; Beauty faced less favorable mix and isolated supplier disruptions; Closures was affected by maintenance issues, weather-related temporary plant closures and investment write-offs.

Which products and end markets drive Aptar’s economics?

End markets explain Aptar’s resilience and volatility. Pharma serves prescription drugs, consumer healthcare, injectables, active materials and digital health. Beauty covers fragrance, skincare, cosmetics, personal care and home care; Closures serves food, beverage and household applications. Different demand cycles diversify revenue but make segment detail essential.

How did each segment perform in Q1 2026?

Pharma sales rose 7% to $438.6 million, although core sales fell 1%. Injectables grew 20% on GLP-1, biologic and antithrombotic demand; consumer healthcare rose 4%, while prescription sales fell 10% as emergency-medicine comparisons normalized. Beauty grew 19% to $363.6 million, with nine currency points and seven acquisition points; core growth was 3%. Closures rose 5% to $180.7 million, with flat core sales.

Where is revenue geographically concentrated?

What strategic turning points shaped AptarGroup?

Aptar’s history matters because it explains the transition from a packaging-component manufacturer into a portfolio of delivery technologies. The company’s official history traces roots to businesses founded in the United States, France and Germany in the 1940s. The important analytical theme is repeated adjacency: Aptar used molding and assembly expertise to move from valves and pumps into closures, then into regulated drug delivery, active materials, services and digital health.

1. 1940s
   Founding companies emerged in the United States, France and Germany, creating the cross-border engineering base behind today’s global footprint.
2. 1960–1980
   The businesses were acquired by Pittway and expanded manufacturing of spray valves and pumps, establishing high-volume component expertise.
3. 1993
   Aptar became a publicly traded NYSE company, giving the business independent access to capital and a public capital-allocation framework.
4. 2018
   The CSP Technologies acquisition added proprietary active-material science and protective packaging, deepening Pharma’s technical differentiation.
5. 2019–2021
   Nanopharm and Gateway Analytical added drug-development services; Voluntis added digital therapeutics; Weihai Hengyu expanded injectable components in China.
6. 2023
   Reporting was realigned into Pharma, Beauty and Closures, making the profit concentration in Pharma easier to see.
7. 2025–2026
   Aptar consolidated 80% of BTY, acquired Sommaplast, expanded the buyback authorization to $600 million and announced Gael Touya as CEO effective September 1, 2026.

What gives AptarGroup a competitive advantage?

Aptar’s moat is strongest when a component is embedded in a regulated product or manufacturing process. Pharma customers may spend years on qualification, compatibility testing and regulatory submissions. After commercialization, switching can require revalidation and supply-chain changes, creating costs far above the component’s physical value.

Which resources are difficult to replicate?

The 2025 annual report highlights injection molding, robotics, clean rooms, high-speed assembly, elastomer and silicone formulation, sterilization and active-material science. Aptar also uses patents, trade secrets and know-how, although no single patent is material. The moat comes from capabilities, customer relationships and regulatory experience reinforcing one another.

Who are the main competitors?

Aptar does not disclose consolidated market share and describes a fragmented competitor set. Price pressure is strongest in Beauty and personal care, including from lower-cost Asian suppliers. Aptar counters with local supply, design support, quality and multi-region service for global customers.

How financially strong is AptarGroup?

FY2025 established a solid earnings base but also showed the trade-off between reinvestment, shareholder returns and leverage. According to the 2025 Form 10-K, revenue increased 5% to $3.78 billion, operating income rose 1% to $501.0 million, net income increased 5% to $392.8 million and diluted EPS rose 7% to $5.89. Operating margin nevertheless declined to 13.3% from 13.8% because product mix, inefficiencies and depreciation offset sales growth.

How does profit convert into cash?

Free cash flow fell from $366.9 million in FY2024 as operating cash flow declined. Capex equaled 7.2% of FY2025 revenue, confirming that Aptar is not asset-light. The key question is whether investment expands Pharma and productivity or mainly maintains the global plant network.

How is capital being allocated?

Aptar returned $485.8 million in FY2025: $365.0 million for about 2.7 million shares and $120.8 million in dividends. That exceeded free cash flow as debt rose after a $600 million, 4.75% note issuance. In Q1 2026, it repurchased 707,000 shares for $100.0 million, paid $30.9 million of dividends and had $500 million of authorization remaining.

Who owns AptarGroup stock, and how is it governed?

Aptar has one common share class and no founder-controlled or dual-class structure. The investor base is institutionally dominated, so voting influence is dispersed among large asset managers and long-term holders rather than concentrated in management. The 2026 proxy statement reported 63,772,670 shares outstanding as of March 13, 2026 and four beneficial owners above 5%.

What does governance signal?

Leadership succession is the key near-term governance event. Aptar’s leadership page states that Gael Touya, a more than 30-year company veteran and current Pharma president, becomes CEO on September 1, 2026. Stephan Tanda remains CEO until then and is expected to advise through year-end. The internal appointment supports continuity around Pharma, but researchers should watch whether capital allocation, margin targets or portfolio priorities change under the new CEO.

What opportunities could accelerate AptarGroup’s growth?

The best opportunities combine healthcare volume growth with technical barriers. Q1 2026 injectables sales rose 20% on GLP-1, biologic and antithrombotic demand. Systemic nasal delivery can combine devices, regulatory services and royalties. Eye care, consumer nasal products and active materials add exposure to diagnostics, wearables and moisture-sensitive medicines.

What does the updated capital plan imply?

The annual report initially expected 2026 capital investment of $260 million to $280 million; the Q1 filing raised expected net cash outlays to $310 million to $320 million. The new range equals roughly 8% of FY2025 sales. It may support capacity and growth, but raises the free-cash-flow hurdle while Aptar continues substantial buybacks.

What risks could weaken AptarGroup’s outlook?

Aptar’s highest-margin businesses depend on customer product success, approvals, intellectual property, quality and supply continuity. Consumer operations face price competition, resin pass-throughs, tariffs and lower-cost suppliers. Its global footprint also creates currency and plant-disruption exposure.

Which risk is most important?

The central risk is margin dilution when growth comes from currency, acquisitions or lower-margin applications. In Q1 2026, reported sales rose 11%, yet constant-currency adjusted EPS declined 8% and adjusted EBITDA margin fell 150 basis points. Core sales, mix and segment margins therefore matter more than headline revenue.

Cybersecurity and quality matter because Aptar runs automated plants, connected devices and regulated production. The 2025 filing reported no material cyber event to date, but disruption could halt manufacturing or expose data. A drug-delivery defect can affect dosing, sterility, recalls and customer regulatory obligations.

Why does AptarGroup’s business model matter for valuation?

An Aptar DCF should separate reported from economic growth. Currency can move revenue without changing local demand, acquisitions can precede synergies, and resin pass-throughs can add sales without unit profit. Core sales are a better starting point, but must be weighted by segment margin; Pharma’s share of incremental revenue drives earnings quality.

Which KPIs belong in an Aptar valuation model?

A model should forecast segment revenue and margins separately, include currency assumptions, keep capex above depreciation during the growth program and avoid treating every buyback as value creation. Terminal assumptions should balance healthcare switching costs against price competition in Beauty and Closures. Comparables should include both packaging and drug-delivery component peers.

What is the key takeaway from AptarGroup analysis?

Aptar occupies an essential layer of the value chain: it makes medicines and consumer products deliverable, protectable and manufacturable at scale. Pharma supplies the moat and most segment profit; Beauty and Closures add scale and diversification. The model is strongest when regulated products, injectables and royalties outgrow lower-margin consumer applications.